Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 187-191

  Mou, Shan ^a   Wang, Qin ^a   Li, Jialin ^a   Shi, Beili ^a   Ni, Zhaohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic glomerulonephritis; L FABP; Progression of renal disease

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; URINARY EXCRETION;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 82955167850     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.018     Document Type: Article

References (23)

1. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
2. Eddy A.A. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994, 5:1273-1287.
3. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296.
4. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001, 357:1601-1608.
5. Zoja C., Benigni A., Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 2004, 13:31-37.
6. Hamilton J.A., Era S., Bhamidipati S.P., Reed R.G. Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc Natl Acad Sci USA 1991, 88:2051-2054.
7. Kees-Folts D., Sadow J.L., Schreiner G.F. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 1994, 45:1697-1709.
8. Arici M., Chana R., Lewington A., et al. Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptorgamma. J Am Soc Nephrol 2003, 14:17-27.
9. Kamijo A., Kimura K., Sugaya T., et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002, 62:1628-1637.
10. Walker P.D., Shah S.V. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988, 81:334-341.
11. Maatman R.G., van de Westerlo E.M., van Kuppevelt T.H., et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992, 288:285-290.
12. Pelsers M.M., Morovat A., Alexander G.J., et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002, 48:2055-2057.
13. Idasiak-Piechocka I., Oko A., Pawliczak E., et al. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant 2010 Dec, 25(12):3948-3956.
14. Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005, 352:15-35.
15. Nakamura T., Sugaya T., Node K., et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 2006, 47:439-444.
16. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2007, 73:465-472.
17. Ferguson Michael A., Vaidya Vishal S., et al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 2010, 77:708-714.
18. Nakamura T., Sugaya T., Koide H. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009, 31:454-459.
19. Kamijo A., Sugaya T., Hikawa A., et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004, 165:1243-1255.
20. Kamijo A., Kimura K., Sugaya T., et al. Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease. J Lab Clin Med 2004, 143:23-30.
21. Kamijo A., Sugaya T., Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006, 374:1-7.
22. Oyama Y., Takeda T., Hama H., et al. Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules. Lab Invest 2005, 85:522-531.
23. Kamijo A., Sugaya T., Hikawa A., et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006, 284:175-182.